Kronos Bio appoints Deborah Knobelman as president and interim CEO, reducing workforce by 83% to enhance shareholder value. The company explores strategic options under Knobelman's leadership, following Norbert Bischofberger's departure. KB-0742 trial for HGSOC progresses.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing